DTP vaccine withdrawal
Connaught Labs' Feb. 23 withdrawal of its diptheria-tetanus-pertussis vaccine adsorbed lot number 8M91039 was initiated after a routine quality assurance inspection. Connaught said it "determined that four vials of Inflogen, an inactivated equine influenza vaccine, in storage at the plant were incorrectly labeled as DTP." The company is coordinating withdrawal activities with FDA. The lot contained 45,909 vials, approximately 19,083 of which were shipped to 1,865 doctors, pharmacists and distributors. Each is being contacted by telephone and telegram, Connaught said. The firm added that there is no evidence that any vials containing Inflogen left the plant.
You may also be interested in...
Cipla has expanded its partnership with Alvotech to cover the commercialization of five biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.
Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.